Coherus Oncology (CHRS) Convertible Debt (2016 - 2025)

Coherus Oncology has disclosed Convertible Debt across 10 years of filings, most recently posting $228.6 million for Q1 2025.

• Convertible Debt for Q1 2025 came in at $228.6 million, up 0.59% year-over-year; the trailing twelve-month figure through Mar 2025 was $228.6 million (up 0.59% YoY), and the FY2024 annual result was $228.2 million, up 0.59% from the prior year.
• Convertible Debt came in at $228.6 million for Q1 2025 at Coherus Oncology, roughly flat from $228.2 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $332.8 million in Q4 2021 to a low of $223.3 million in Q1 2021.
• The 5-year median for Convertible Debt is $226.2 million (2023), against an average of $232.3 million.
• Across the five-year window, Convertible Debt soared 183.19% in 2021 and slumped 32.21% in 2022, its largest moves.
• Coherus Oncology's Convertible Debt stood at $332.8 million in 2021, then plunged by 32.21% to $225.6 million in 2022, then climbed by 0.58% to $226.9 million in 2023, then increased by 0.59% to $228.2 million in 2024, then gained by 0.15% to $228.6 million in 2025.
• The last three Convertible Debt figures came in at $228.6 million (Q1 2025), $228.2 million (Q4 2024), and $227.9 million (Q3 2024), per Business Quant data.